Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRIW) Gross Margin (2020 - 2025)

Biofrontera has reported Gross Margin over the past 6 years, most recently at 82.4% for Q4 2025.

  • Quarterly results put Gross Margin at 82.4% for Q4 2025, up 2437.0% from a year ago — trailing twelve months through Dec 2025 was 73.71% (up 2356.0% YoY), and the annual figure for FY2025 was 73.71%, up 2357.0%.
  • Gross Margin for Q4 2025 was 82.4% at Biofrontera, up from 70.74% in the prior quarter.
  • Over the last five years, Gross Margin for BFRIW hit a ceiling of 112.8% in Q4 2023 and a floor of 72.27% in Q4 2022.
  • Median Gross Margin over the past 5 years was 70.74% (2025), compared with a mean of 67.81%.
  • Biggest five-year swings in Gross Margin: tumbled -17030bps in 2022 and later soared 18507bps in 2023.
  • Biofrontera's Gross Margin stood at 98.03% in 2021, then plummeted by -174bps to 72.27% in 2022, then soared by 256bps to 112.8% in 2023, then tumbled by -49bps to 58.03% in 2024, then surged by 42bps to 82.4% in 2025.
  • The last three reported values for Gross Margin were 82.4% (Q4 2025), 70.74% (Q3 2025), and 70.74% (Q2 2025) per Business Quant data.